Grey Sky Venture Partners
VC Fund
Bellevue, United States
Grey Sky Venture Partners is a new early-stage investment firm that invests in the areas of healthcare sectors.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Grey Sky Venture Partners invests in
Stages Grey Sky Venture Partners invests in
Countries Grey Sky Venture Partners invests in
Investment Focus
Industry
- Biotechnology 4 (57%)
- Medical 2 (29%)
- Health Care 2 (29%)
- Therapeutics 2 (29%)
- Product Research 2 (29%)
Stage
- Series A 4 (57%)
- Seed 2 (29%)
- Series B 1 (14%)
Country
- United States 4 (57%)
- Canada 2 (29%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Winterlight Labs
|
Winterlight Labs builds technology that can quickly and accurately detect signs of cognitive impairment from a sample of speech.WinterLight Labs develops a novel AI technology platform that can quickly and accurately quantify speech and language patterns to help detect and monitor cognitive and mental diseases. This platform can analyze naturalspeech to detect and monitor dementia, aphasia, and various cognitive conditions. Using a short one-minute sample of speech, WinterLight can characterize the speaker's cognitive, acoustic, and linguistic state, including lexical diversity, syntactic complexity, semantic content, and articulation.Winterlight was founded in 2015 and is based in Toronto, Canada. | $4.2M / Series A / Nov 18, 2019 | |
AmacaThera
|
AmacaThera is a clinical-stage company based in Toronto. AmacaThera is redefining how therapeutics are delivered. AmacaThera has developed a platform hydrogel technology that addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. AmacaThera’s lead product addresses post-operative painand consequently may have an impact on the opioid crisis. | $2.7M / Seed / Oct 03, 2019 | |
Modulim
|
Modulim is a leader in a breakthrough technology in tissue and vascular assessment,called, spatial frequency domain imaging or SFDI. Powered by SFDI, our Clarifi Imaging System helps identify patients at risk of complications such as diabetic foot ulcers and amputations due to potential compromised circulation so clinicians can provide more timelyintervention and save patients' limbs and lives. | $7M / Series B / Jan 23, 2019 | |
HepaTx
|
HepaTx is developing regenerative medicine solutions to address the need for better therapies for life-threatening liver diseases. The technology invented at Stanford University enables efficient hepatocyte production for therapeutic purposes. Its therapeutics can replace lost liver function to treat those with end-stage of liver disease,potentially saving the cost and morbidity of whole organ transplant. | $2.1M / Seed / Aug 20, 2018 | |
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $10M / Series A / Nov 27, 2017 | |
|
Modulim
|
Modulim is a leader in a breakthrough technology in tissue and vascular assessment,called, spatial frequency domain imaging or SFDI. Powered by SFDI, our Clarifi Imaging System helps identify patients at risk of complications such as diabetic foot ulcers and amputations due to potential compromised circulation so clinicians can provide more timelyintervention and save patients' limbs and lives. | $2.9M / Series A / Nov 16, 2017 | |
Sonavex
|
Sonavex is committed to improving outcomes for surgical patients by using cutting-edge imaging technology to provide clinicians with visualization of critical data -- directly at the point of care. The company's technology offers a proprietary technology platform that utilizes ultrasound to detect blood clots after surgery, enabling cliniciansto measure critical intravascular flow metrics to detect post-operative clots directly at the point of care and improve outcomes. | $4.5M / Series A / Apr 24, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Grey Sky Venture Partners invest in?
Grey Sky Venture Partners invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Grey Sky Venture Partners last invest?
The most recent investment recorded for Grey Sky Venture Partners closed in Nov 2019. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
